Reaction
Ileal Ulcer reporting signals
As of the last recalculation, Ileal Ulcer appears in 993 FAERS reports alongside 24 co-occurring drug terms. The strongest observed disproportionality signal is ADALIMUMAB-AATY (PRR 37.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Adalimumab-Aaty | 78 | 37.4 | 37.5 |
| Adalimumab-Fkjp | 76 | 37.2 | 37.2 |
| Adalimumab-Adaz | 82 | 35.4 | 35.5 |
| Basiliximab | 18 | 32.7 | 32.7 |
| Vedolizumab | 118 | 32.4 | 32.5 |
| Naltrexone Hydrochloride And Bupropion Hydrochloride | 9 | 22.3 | 22.3 |
| Tacrolimus Ointment 0.1% | 96 | 17.8 | 17.8 |
| Tacrolimus Extended-Release Capsules | 96 | 17.7 | 17.7 |
| Canakinumab | 9 | 17.6 | 17.6 |
| Zidovudine | 11 | 17.4 | 17.4 |
| Sirolimus | 11 | 17.3 | 17.3 |
| Infliximab-Dyyb | 23 | 16.9 | 16.9 |
| Ganciclovir | 8 | 16.5 | 16.5 |
| Everolimus Tablets | 13 | 16.5 | 16.5 |
| Ganciclovir Sodium | 8 | 16.0 | 16.0 |
| Tacrolimus | 105 | 15.6 | 15.6 |
| Olmesartan Medoxomil | 26 | 15.5 | 15.5 |
| Mycophenilic Acid | 14 | 14.3 | 14.4 |
| Ustekinumab | 63 | 13.7 | 13.7 |
| Entecavir | 7 | 12.6 | 12.7 |
| Sevelamer Carbonate | 5 | 9.2 | 9.2 |
| Encorafenib | 4 | 8.5 | 8.5 |
| Risankizumab-Rzaa | 29 | 7.6 | 7.6 |
| Isotretinoin | 12 | 5.1 | 5.1 |